IMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers
IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer.
- IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer.
- The collaboration brings together IMVARIA’s engineering expertise in digital biomarkers with Mayo Clinic’s know-how and data assets as part of the Validate pillar of Mayo Clinic Platform.
- In 2023, over 125,000 deaths have occurred due lung cancer, and nearly a quarter-of-a-million new lung cancer cases were identified.
- Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.